Hospital  Internal MedicineⅢ 

Research Interests 【 display / non-display

  • Hematology

Graduating School 【 display / non-display


    Akita University   Faculty of Medicine   Graduated

Graduate School 【 display / non-display


    Akita University  Graduate School, Division of Medicine  Doctor's Course  Completed

Campus Career 【 display / non-display

  • 2023.04

    Akita University   Hospital   Internal MedicineⅢ   Lecturer  

  • 2022.04

    Akita University   Hospital   Pharmaceutical Management Center   Lecturer  

  • 2020.09

    Akita University   Hospital   Pharmaceutical Management Center   Assistant Professor  

Research Areas 【 display / non-display

  • Life Science / Hematology and medical oncology


Thesis for a degree 【 display / non-display

  • MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.

    Akihiro Kitadate, Sho Ikeda, KazuakiTeshima, Mitsugu Ito, Ikumi Toyota, Naoko Hasunuma, Naoto Takahashi, Tomomitsu Miyagaki, Makoto Sugaya, Hiroyuki Tagawa 

    Oncogene  35 ( 28 ) 3692 - 3704   2016.03  [Refereed]

    Domestic Co-author


Research Achievements 【 display / non-display

    ◆Original paper【 display / non-display

  • Comment on skin biopsies for diagnosing intravascular lymphoma: A retrospective study of diagnostic accuracy.

    Naoko Enzan, Akihiro Kitadate, Michihiro Kono

    Journal of the American Academy of Dermatology     2023.01  [Refereed]

    Research paper (journal)   Domestic Co-author


  • High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma.

    Wataru Kuroki, Akihiro Kitadate, Koichi Ishiyama, Yoshihiro Kameoka, Naoto Takahashi

    International Journal of Hematology   116 ( 5 ) 712 - 722   2022.11  [Refereed]

    Research paper (journal)   Domestic Co-author


  • Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence

    Akihiro Kitadate

    Cancer Science   112 ( 9 ) 3645 - 3654   2021.09  [Refereed]

    Research paper (journal)   Domestic Co-author

    CD38 expression on myeloma cells is a critical factor affecting the early response to the anti-CD38 antibody daratumumab. However, factors affecting CD38 expression in untreated multiple myeloma are not fully elucidated. In this study, we found that CD38 expression was significantly lower in myeloma patients with the translocation t(11;14)-associated immature plasma cell phenotype, and particularly in those expressing B-cell-associated genes such as PAX5 and CD79A. CD138, a representative marker of plasmacytic differentiation, was also significantly lower in these patients, suggesting that CD38 expression may be associated with the differentiation and maturation stages of myeloma cells. Furthermore, the BCL2/BCL2L1 ratio, a response marker of the BCL2 inhibitor venetoclax, was significantly higher in patients with the immature phenotype expressing B-cell-associated genes. The BCL2/BCL2L1 ratio and CD38 expression were significantly negatively correlated. We also confirmed that patients with translocation t(11;14) expressing B-cell-associated genes were indeed less sensitive to daratumumab-mediated direct cytotoxicity but highly sensitive to venetoclax treatment in ex vivo assays. Moreover, all-trans-retinoic acid, which enhances CD38 expression and induces cell differentiation in myeloma cells, reduced B-cell marker expression and the BCL2/BCL2L1 ratio in myeloma cell lines, leading to reduced efficacy of venetoclax. Venetoclax specifically induces cell death in myeloma with t(11;14), although why patients with translocation t(11;14) show BCL2 dependence is unclear. These results suggest that BCL2 dependence, as well as CD38 expression, are deeply associated with the differentiation and maturation stages of myeloma cells. This study highlights the importance of examining t(11;14) and considering cell maturity in myeloma treatment strategies.


  • Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma

    Kitadate A.

    Cancer Medicine   9 ( 15 ) 5509 - 5518   2020.08  [Refereed]

    Research paper (journal)   Domestic Co-author


  • Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice

    Terao T, Machida Y, Tsushima T, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue K.

    British Journal of Haematology     2020  [Refereed]

    Research paper (journal)   Domestic Co-author


  • display all >>

    ◆Other【 display / non-display

  • Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma

    Ikeda S, Abe F, Matsuda Y, Kitadate A, Takahashi N, Tagawa H.

    Cancer Science     2020  [Refereed]

    Domestic Co-author


  • Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma

    Abe F, Kitadate A, Ikeda S, Yamashita J, Nakanishi H, Takahashi N, Asaka C, Teshima K, Miyagaki T, Sugaya M, Tagawa H.

    Oncotarget   8 ( 5 ) 7572 - 7585   2017

    Domestic Co-author


  • Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis

    FUJISHIMA Masumi, TAKAHASHI Naoto, FUJISHIMA Naohito, KITADATE Akihiro, GUO Yongmei, WATANABE Atsushi, UBUKAWA Kumi, NARA Miho, YOSHIOKA Tomoko, KAMEOKA Yoshihiro

    Rinsho Ketsueki ( The Japanese Society of Hematology )  58 ( 7 ) 743 - 748   2017

    <p>A 64-year-old woman was admitted to our hospital to undergo allogeneic stem cell transplantation. She was diagnosed with polycythemia vera with a JAK2 V617F mutation 7 years ago. She was administered ruxolitinib for splenomegaly two years prior to admission but this was discontinued because of progressive pancytopenia. One months after cessation of ruxolitinib, she developed acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis. Although she achieved complete remission after induction therapy, 8-finger-breadth splenomegaly remained below the left costal margin. Ruxolitinib was re-administered following two courses of consolidation therapy. She underwent unrelated peripheral blood stem cell transplantation. Ruxolitinib was administered until the day before transplantation, and the spleen was palpated in 4-finger breadth below costal arc. Neutrophil engraftment was achieved 13 days after transplantation. In allogeneic stem cell transplantation, splenomegaly is one of the risk factors for engraftment failure and/or therapy-related mortality. Hence, a smaller spleen size can theoretically improve the outcome after transplantation. The administration of ruxolitinib prior to transplantation may have contributed to engraftment with a non-invasive reduction in the size of the spleen.</p>